New Generation mRNA Booster Vaccine Against Emerging VOCs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

2000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-31

Study Completion Date

2023-05-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary：Objectives ：SafetyTo describe the safetyprofile of all participants in each group up to 6months post-dose.Immunogenicity：To demonstrate the superiorityof neutralizing antibodyresponse in terms of geometric mean titers (GMT) of mRNA vaccine compare with inactive vaccine28 days post dose. Secondary:Immunogenicity

1. To describe binding antibodyprofile at D01,D08, D15, D29,D91 and D181 of eachstudy group.
2. To describe the neutralizing antibody profile atD08,D15,D91 and D181of 600 participants for each studyintervention group. Exploratory:Cell-mediated immunity To describe the cellular immuneresponse profile at D01, D08, D15and D29, in a subset of 30 participants for each study group.

Efficacy:To describe the occurrence of virologically-confirmed COVID-19 like illness and serologically confirmed SARS-CoV-2 infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above

NCT05381350

COVID-19

COMPLETED PHASE3

mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs

NCT05686161

Immunogenicity Safety Efficacy

UNKNOWN PHASE3

Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19

NCT05079217

COVID-19

UNKNOWN PHASE4

A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above

NCT05144139

COVID-19 Pandemic

COMPLETED PHASE1/PHASE2

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

NCT05960097

SARS-CoV-2 COVID-19

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Endpoints:Safety Endpoints- Occurrence of unsolicited systemic AEs reported in the 30 minutes after each injection.

Occurrence of solicited injection site reactions and systemicreactions occurring up to 7 days post-dose.

Occurrence of unsolicited non-serious AEs reported up to 28 dayspost-dose. Occurrence of SAEs and AESIs up to 6 months throughout the study. Immunogenicity Endpoints:GMT of neutralizing antibody will be measured with the neutralization assayon D01,D29.

Binding antibody titers to full length SARS-CoV-2 Spike (S) protein will be measured for each study intervention group with the ELISA method

* Antibody titer on D01, D08, D15, D29, D91, D181
* Fold-rise in antibody titer at D08, D15, D29, D91 and D181 post vaccination relative to D01
* 4-fold-rise in antibody titer at D08, D15, D29, D91, and D181 relative to D01 Neutralizing antibody titers will be measured with the neutralization assay
* Antibody titer on D08, D15, D29, D91 and D181
* Fold-rise (fold rise in serum neutralization titer post vaccination relative to D01) at D08, D15, D29, D91 and D181
* 4-fold rise in serum neutralization titer \[post/pre\] relative to D01 at D08, D15, D29, D91 and D181
* Occurrence of neutralizing antibody seroconversion, defined as baseline values below LLOQ at baseline with detectable neutralization titer above assay lower limit of quantification at D08, D15, D29, D91 and D181INF-γ, IL-4 and IL-2 will be measured in whole blood and/or cryopreserved PBMC following stimulation with pools of S
* ExploratoryCell-mediated immunity To describe the cellular immune response profile at D01, D08, D15 and D29, in a subset of 30 participants for each study group antigen peptides.

Virologically-confirmed COVID 19 like illness as defined by specified clinical symptoms and signs and confirmed by a positive result for SARS-CoV-2 nucleic acid viral detection assay.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immunogenicity Efficacy Safety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

a randomized observer-blinded parallel controlled trial：Experimental group（mRNA vaccine） and positive control group（inactive vaccine）

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

This study uses a double blinded design, and the investigators and participants will all remain blinded before unblinding and do not know which group the participant belongs to.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SW-BIC-213

Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular

Group Type EXPERIMENTAL

SW-BIC-213

Intervention Type BIOLOGICAL

The patient will take a single 25 μg dose mRNA vaccine SW-BIC-213.

SARS-Cov-2 Vaccina(Vero Cell ) Inactivated

Intervention Name: COVID-19 Inactivated Vaccine Type : Control Vaccine Dose :Inactive Unit Dose Strength(s) : 0.5ml; Route of Administration Intramuscular : injection Intramuscular

Group Type ACTIVE_COMPARATOR

SARS-Cov-2 Vaccina(Vero Cell ) Inactivated

Intervention Type BIOLOGICAL

The patient will take a third dose of COVID-19 Inactivated vaccine.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SW-BIC-213

The patient will take a single 25 μg dose mRNA vaccine SW-BIC-213.

Intervention Type BIOLOGICAL

SARS-Cov-2 Vaccina(Vero Cell ) Inactivated

The patient will take a third dose of COVID-19 Inactivated vaccine.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participant is willing and able to give written informed consent for participation in the study.
2. Male or Female, aged 18 years or above and in good health as determined by study clinician.
3. Female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunization continuously until 3 months after boost immunization.
4. In the Investigator's opinion, is able and willing to comply with all trial requirements.
5. Subjects had completed the 2-dose series vaccination of COVID-19 inactivated vaccine at least .

24 weeks with the completed the 2-dose Series as the primary vaccination according to the product label.

Exclusion Criteria

The participant may not enter the study if ANY of the following apply:

1. Confirmed cases, suspected cases or asymptomatic cases of COVID-19;
2. Self-reported history of SARS and MERS infection;
3. Receipt of live attenuated vaccine within one month prior to vaccination and other vaccines within 14 days prior to vaccination;
4. Receipt of any SARS-COV-2 vaccine after last dose of primary vaccination
5. Participants who are pregnant at enrolment or planning to become pregnant during the first 3 months following vaccination.
6. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccines.
7. History of allergic disease or reactions likely to be exacerbated by any component of study vaccines.
8. Any history of anaphylaxis to any component of vaccine.
9. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or continuous use of anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran, edoxaban), or prior history of significant bleeding or bruising following IM injections or venipuncture.
10. Suspected or known current alcohol or drug dependency
11. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
12. Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness (mild/moderate well controlled comorbidities are allowed).
13. Scheduled elective surgery during the trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes